Every year, the BIO International Convention brings together more than 20,000 leaders from across the global life sciences ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...

Bristol Myers Squibb has touted its strengthened collaboration with Nvidia as aiming to build the “most powerful AI factory ...

A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...

As biomanufacturing investment accelerates, workforce readiness has emerged as a critical bottleneck. | Ohio’s $30M training ...

After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum. The ...

For emerging biotech companies, the race to IND is no longer defined by speed alone. | Lonza explains why early de-risking ...

Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, ...

KIT-targeting antibody biotech Jasper Therapeutics is being renewed via a merger with Nasdaq-listed Kira Pharmaceuticals—but ...

Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for ...

Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a ...